# Bruce E. Sands

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/bruce-e-sands/

## Facts

| Field | Value |
| --- | --- |
| Citations | 66,805 |
| Field | Inflammatory Bowel Disease |
| h-index | 108 |
| i10-index | 366 |
| Last Known Institution | Icahn School of Medicine at Mount Sinai |
| OpenAlex ID | https://openalex.org/A5017140014 |
| ORCID iD | https://orcid.org/0000-0001-5762-5042 |
| Works | 1,067 |

## Researcher papers

Showing 12 of 13.

- [Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/vedolizumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD](https://scholariq.org/papers/stride-ii-an-update-on-the-selecting-therapeutic-targets-in-inflammatory-bowel/)
- [Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target](https://scholariq.org/papers/selecting-therapeutic-targets-in-inflammatory-bowel-disease-stride-determining/)
- [Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease](https://scholariq.org/papers/ustekinumab-as-induction-and-maintenance-therapy-for-crohn-s-disease/)
- [Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/tofacitinib-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial](https://scholariq.org/papers/secukinumab-a-human-anti-il-17a-monoclonal-antibody-for-moderate-to-severe-crohn/)
- [Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/ustekinumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Development of the Crohnʼs disease digestive damage score, the Lémann score](https://scholariq.org/papers/development-of-the-crohn-s-disease-digestive-damage-score-the-lemann-score/)
- [Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial](https://scholariq.org/papers/ustekinumab-versus-adalimumab-for-induction-and-maintenance-therapy-in-biologic/)
- [Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity](https://scholariq.org/papers/ulcerative-colitis-is-characterized-by-a-plasmablast-skewed-humoral-response/)
- [IL-12 and IL-23 pathway inhibition in inflammatory bowel disease](https://scholariq.org/papers/il-12-and-il-23-pathway-inhibition-in-inflammatory-bowel-disease/)
- [Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial](https://scholariq.org/papers/guselkumab-plus-golimumab-combination-therapy-versus-guselkumab-or-golimumab/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Autoimmune and Inflammatory Disorders](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders/)

## Researcher university

- [Icahn School of Medicine at Mount Sinai](https://scholariq.org/institutions/icahn-school-of-medicine-at-mount-sinai/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.